Here’s what Americans needs to know.
Millions of seniors enrolled in Medicare could soon pay more for their prescription drug coverage as a temporary federal assistance program comes to an end. The development presents a new policy challenge for President Donald Trump, whose administration has emphasized lowering healthcare and prescription drug costs. Administration officials argue that ending the subsidies will reduce government spending and strengthen the Medicare marketplace, while opponents say some beneficiaries may experience higher monthly premiums starting in 2027.
The issue comes as healthcare affordability remains a top concern for retirees and older Americans living on fixed incomes. Prescription drug costs, Medicare premiums, and everyday household expenses continue to be major priorities for many voters heading into the midterm election season.
President Trump has repeatedly highlighted his administration’s efforts to reduce prescription drug prices through expanded competition, price negotiations, and other reforms designed to make medications more affordable for American families.
However, healthcare policy experts say the expiration of a temporary Medicare Part D subsidy program could offset some of those savings for certain beneficiaries by increasing monthly insurance premiums.
Medicare Part D Subsidies Set To End
The Centers for Medicare & Medicaid Services (CMS) confirmed that the temporary Medicare Part D premium stabilization program will expire at the end of this year and will not continue into 2027.
The subsidy program was introduced during the Biden administration to help stabilize Medicare prescription drug plans after changes made through the Inflation Reduction Act.
When the program was first announced in 2024, federal officials indicated it could remain in place for at least three years. Instead, CMS has decided to end the initiative a year earlier than originally expected.
Medicare Part D provides optional prescription drug coverage through private insurance companies. Beneficiaries can purchase stand-alone drug plans or receive prescription coverage through many Medicare Advantage plans.
The program helps cover both generic and brand-name medications used by millions of older Americans each year.
Critics Say Seniors Could Pay More
Healthcare organizations argue that ending the temporary subsidies may result in higher monthly premiums for many Medicare beneficiaries.
Juliette Cubanski, vice president and director of the Program on Medicare Policy at KFF, said the Trump administration has pursued several initiatives aimed at lowering prescription drug prices.
At the same time, she noted that eliminating the additional premium assistance could move costs in the opposite direction for millions of seniors.
According to Cubanski, reducing drug prices remains an important goal, but ending the subsidy program may leave some retirees paying more each month for their Medicare prescription drug coverage.
She noted that many seniors carefully manage every dollar of their monthly budget, making even relatively modest premium increases significant.
Trump Administration Defends Decision
The Trump administration says the temporary subsidies have accomplished their purpose and are no longer necessary.
CMS Administrator Dr. Mehmet Oz argued that taxpayers should not continue providing billions of dollars to private insurance companies through what was always intended to be a short-term program.
Oz said the Medicare prescription drug market has stabilized enough that the subsidies can safely end.
He also emphasized that many beneficiaries are expected to see little or no increase in their monthly costs.
According to CMS, more than 85 percent of beneficiaries enrolled in the affected stand-alone Medicare Part D plans will still have access to a plan that either costs less than their current coverage or increases by less than $10 per month.
Federal officials also maintain that some Medicare recipients could actually pay lower premiums next year depending on the plan they choose during open enrollment.
New Cost Estimates Coming Soon
CMS reported that the national average monthly bid submitted by insurance companies for 2027 has increased to $296.05, compared with $239.27 one year earlier.
However, those figures represent insurer bids rather than the actual premiums seniors will pay.
Official Medicare Part D premium estimates for consumers are expected to be released later this year, likely in September.
Those numbers will provide beneficiaries with a clearer picture of what they can expect to pay in 2027.
Billions Spent On Temporary Program
According to the Government Accountability Office, the temporary Medicare subsidy program cost approximately $9.8 billion during 2025 and 2026.
More than 23 million Americans were enrolled in stand-alone Medicare Part D prescription drug plans during 2025.
Supporters of ending the program argue that continuing billions of dollars in subsidies after market conditions have stabilized would place an unnecessary burden on taxpayers.
Administration officials say their focus remains on lowering prescription drug costs rather than directing additional federal funding toward insurance companies.
Healthcare Groups Push Back
Not everyone agrees with that assessment.
Several healthcare advocacy organizations argue that ending the subsidies now could place additional financial pressure on retirees already dealing with higher grocery prices, housing expenses, and other rising costs.
Leslie Dach, founder of Protect Our Care, argued that the federal savings are relatively modest compared to the potential financial impact on Medicare beneficiaries.
David Lipschutz, co-director of the Center for Medicare Advocacy, also questioned the timing of the decision.
He suggested that ending the subsidies could encourage more seniors to enroll in Medicare Advantage plans, which some analysts argue cost the Medicare program more overall.
Healthcare advocates also believe administration officials may point to ending the subsidies as part of broader efforts to reduce federal spending and eliminate programs viewed as unnecessary.
Medicare Costs Remain A Key Issue
Healthcare affordability continues to rank among the biggest concerns for Americans approaching retirement or already enrolled in Medicare.
Cubanski noted that the subsidy program reduced average Medicare Part D premiums by approximately $16 per month during 2026.
Considering that the average stand-alone Medicare Part D premium was about $36 per month, she said many beneficiaries would have paid substantially more without the temporary assistance.
For seniors living on fixed incomes, even relatively small increases in monthly healthcare costs can have a noticeable impact on household budgets.
What Happens Next?
Millions of Medicare beneficiaries are expected to learn more about their prescription drug plan costs when CMS releases official 2027 premium information later this year.
Until then, both supporters and critics of the policy are making their case.
The Trump administration argues that ending the temporary subsidies reflects responsible stewardship of taxpayer dollars while continuing its broader effort to lower prescription drug prices through market reforms.
Critics, meanwhile, contend that some retirees could face higher monthly costs despite those broader initiatives.
As healthcare remains one of the most important issues for older Americans, the future of Medicare prescription drug costs is likely to stay at the center of the national conversation throughout the months ahead.
Bottom Line: The Trump administration says the Medicare Part D market has recovered enough to end billions of dollars in temporary subsidies, while healthcare advocates warn that some seniors could still see higher monthly premiums. With official 2027 Medicare costs expected later this year, millions of retirees will soon find out how the changes affect their own budgets.